Epigenetics Market is Expected to Reach $4.3 Billion | MarketsandMarkets.
12 janv. 2024 07h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Epigenetics market in terms of revenue was estimated to be worth $1.8 billion in 2023 and is poised to reach $4.3 billion by 2028, growing at a CAGR of...
K36 Therapeutics Named “Overall BioPharma Startup of the Year” By BioTech Breakthrough
08 nov. 2023 08h05 HE
|
BioTech Breakthrough
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program...
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
09 août 2023 16h05 HE
|
Cyclacel
- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host...
Epigenetics Market is Expected to Reach $3.9 billion | MarketsandMarkets.
03 juil. 2023 08h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, July 03, 2023 (GLOBE NEWSWIRE) -- In the near future, the epigenetics industry is poised for remarkable advancements and transformative impact in various fields. Epigenetics, the study of...
Fluidigm Announces Second Quarter 2020 Financial Results
06 août 2020 16h05 HE
|
Fluidigm Corporation
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
Fluidigm to Present at Upcoming Health Care Investor Conferences
13 mai 2020 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm and the Icahn School of Medicine at Mount Sinai Collaborate on Landmark Single-Cell Study of the Human Epigenome
27 août 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Cancer Biomarkers Market To Reach USD 32.25 Billion By 2026 | Reports And Data
21 mai 2019 12h16 HE
|
Reports And Data
High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favourable research funding scenario are key factors contributing to high CAGR...
Fluidigm Announces First Multimodal Single-Cell Application for the C1
10 juil. 2018 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced a new bimodal single‑cell application...
Elsevier Launches New Stem Cell Book Series
23 mai 2017 04h00 HE
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - May 23, 2017) - Elsevier, the information analytics company specializing in science and health, today announced a new book series, Advances in Stem Cells and their...